Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;60(2):4063-4077.
doi: 10.1111/ejn.16421. Epub 2024 May 21.

Psychedelic therapy in depression and substance use disorders

Nur Damla Korkmaz  1   2   3 , Ugur Cikrikcili  4   5 , Merve Akan  6 , Emrah Yucesan  7
Affiliations
Review

Psychedelic therapy in depression and substance use disorders

Nur Damla Korkmaz et al. Eur J Neurosci. 2024 Jul.

Abstract

Psychoactive substances obtained from botanicals have been applied for a wide variety of purposes in the rituals of different cultures for thousands of years. Classical psychedelics from N,N'-dimethyltryptamine, psilocybin, mescaline and various lysergamides cause specific alterations in perception, emotion and cognition by acting through serotonin 5-HT2A receptor activation. Lysergic acid diethylamide, the first famous breakthrough in the field, was discovered by chance by Albert Hoffman in the Zurich Sandoz laboratory in 1943, and studies on its psychoactive effects began to take place in the literature. Studies in this area were blocked after the legislation controlling the use and research of psychedelic drugs came into force in 1967, but since the 1990s, it has started to be a matter of scientific curiosity again by various research groups. In particular, with the crucial reports of psychotherapy-assisted psilocybin applications for life-threatening cancer-related anxiety and depression, a new avenues have been opened in the treatment of psychiatric diseases such as treatment-resistant depression and substance addictions. An increasing number of studies show that psychedelics have a very promising potential in the treatment of neuropsychiatric diseases where the desired efficiency cannot be achieved with conventional treatment methods. In this context, we discuss psychedelic therapy, encompassing its historical development, therapeutic applications and potential treatment effects-especially in depression, trauma disorders and substance use disorders-within the framework of ethical considerations.

Keywords: anxiety; depression; neurobiology; psychedelics; substance disorders.

PubMed Disclaimer

References

REFERENCES

    1. Abuse, N. I.o. D. (1999). Cocaine abuse and addiction. National Institute on Drug Abuse.
    1. Agin‐Liebes, G. I., Malone, T., Yalch, M. M., Mennenga, S. E., Ponte, K. L., Guss, J., Bossis, A. P., Grigsby, J., Fischer, S., & Ross, S. (2020). Long‐term follow‐up of psilocybin‐assisted psychotherapy for psychiatric and existential distress in patients with life‐threatening cancer. Journal of Psychopharmacology, 34, 155–166. https://doi.org/10.1177/0269881119897615
    1. Almeida, J. R., Versace, A., Hassel, S., Kupfer, D. J., & Phillips, M. L. (2010). Elevated amygdala activity to sad facial expressions: A state marker of bipolar but not unipolar depression. Biological Psychiatry, 67, 414–421. https://doi.org/10.1016/j.biopsych.2009.09.027
    1. Baliki, M. N., Geha, P. Y., Apkarian, A. V., & Chialvo, D. R. (2008). Beyond feeling: Chronic pain hurts the brain, disrupting the default‐mode network dynamics. The Journal of Neuroscience, 28, 1398–1403. https://doi.org/10.1523/JNEUROSCI.4123-07.2008
    1. Barrett, F. S., Bradstreet, M. P., Leoutsakos, J. S., Johnson, M. W., & Griffiths, R. R. (2016). The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. Journal of Psychopharmacology, 30, 1279–1295. https://doi.org/10.1177/0269881116678781

MeSH terms